Wang Fu-Sheng, Trester Cathy
R&D Department, Sysmex America, Mundelein, Illinois 60060, USA.
Int J Hematol. 2004 May;79(4):322-7. doi: 10.1532/ijh97.03091.
Hematopoietic stem cell (HSC) plasticity and its clinical application have been studied profoundly in the past few years. Recent investigations indicate that HSC and other bone marrow stem cells can develop into other tissues. Because of the high morbidity and mortality of myocardial infarction and other heart disorders, myocardial regeneration is a good example of the clinical application of HSC plasticity in regenerative medicine. Preclinical studies in animals suggest that the use of this kind of treatment can reconstruct heart blood vessels, muscle, and function. Some clinical study results have been reported in the past 2 years. In 2003, reports of myocardial regeneration treatment increased significantly. Other studies include observations on the cell surface markers of transplanted cells and treatment efficacy. Some investigations, such as HSC testing, have focused on clinical applications using HSC plasticity and bone marrow transplantation to treat different types of disorders. In this review, we focus on the clinical application of bone marrow cells for myocardial regeneration.
在过去几年中,造血干细胞(HSC)的可塑性及其临床应用得到了深入研究。最近的研究表明,造血干细胞和其他骨髓干细胞可以发育成其他组织。由于心肌梗死和其他心脏疾病的高发病率和死亡率,心肌再生是造血干细胞可塑性在再生医学中临床应用的一个很好的例子。动物实验研究表明,使用这种治疗方法可以重建心脏血管、肌肉和功能。在过去两年中已经报道了一些临床研究结果。2003年,心肌再生治疗的报道显著增加。其他研究包括对移植细胞的细胞表面标志物和治疗效果的观察。一些研究,如造血干细胞测试,专注于利用造血干细胞可塑性和骨髓移植治疗不同类型疾病的临床应用。在这篇综述中,我们重点关注骨髓细胞在心肌再生中的临床应用。